Abstract:Die massiven wissenschaftlichen Aktivitäten zur Bewältigung der Coronapandemie haben für bestimmte intensivmedizinisch relevante Syndrome neue Blickwinkel und Perspektiven eröffnet. Neben der Sepsis betrifft dies das akute Lungenversagen als schwerste Manifestation der COVID-19-Infektion. In diesem Beitrag soll untersucht werden, ob sich daraus bereits neue Empfehlungen zur Diagnostik und Therapie des ARDS im Allgemeinen ableiten lassen. ARDS is a syndrome that can develop as a result of various underlying diseases. For a long time, the prevailing belief was that the course of the disease was comparable regardless of the underlying disease. However, even before the COVID-19 pandemic, it was suspected that there were different manifestations that could be treated more individually and thus reduce the high mortality rate of ARDS, which has remained unchanged for years. The various findings on the heterogeneity of the course of the disease in COVID-related ARDS appear to confirm these assumptions. It is therefore to be expected that the diagnosis and treatment of non-COVID-related ARDS will also have to be individualised according to such phenotypes in the future. However, as long as the effectiveness of such strategies has not been proven in clinical trials, the current recommendations for ARDS therapy will remain valid for the time being. However, the adjustments already formulated in this context to individual pathophysiological conditions with regard to respiratory mechanics, ventilation-perfusion distribution and possible cardiac dysfunction should be made more meticulously than has usually been the case to date. Die Letalität des ARDS bleibt trotz Beachtung der aktuellen Therapieempfehlungen unverändert. Bereits vor der COVID-19-Pandemie zeichnete sich ab, dass die Differenzierung des ARDS in verschiedene Phänotypen zusätzliche Therapieoptionen zulassen könnte. Insbesondere die Unterscheidung zwischen hyper- und hypoinflammatorischen Verläufen schien in dieser Hinsicht erfolgversprechend. Die im Rahmen der COVID-Pandemie gewonnenen Erkenntnisse zu heterogenen Krankheitsverläufen und entsprechend individualisierten Therapiestrategien lassen sich mit dieser Annahme in Einklang bringen. Es erscheint daher auch beim nicht COVID-bedingten ARDS sinnvoll, Subgruppen mit unterschiedlicher Krankheitsausprägung zu identifizieren. Die Steuerung einer entsprechend individualisierten Therapie mithilfe von Biomarkern ist dabei vielversprechend. Article published online: 08 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Akute Lungenversagen (ARDS): neue Perspektiven in Diagnostik und Therapie

Pathophysiologie des akuten Lungenversagens (ARDS)

ARDS-Diagnostik und -Therapie nach der Coronapandemie – alles beim Alten?

Potenzial von KI für die Behandlung des akuten Lungenversagens (ARDS)

Acute respiratory distress syndrome

Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management

Acute lung injury - from pathophysiology to treatment.

Innovations in protective mechanical ventilation for acute respiratory distress syndrome management

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Recent advances in the understanding and management of ARDS

Pneumomediastinum and pneumothorax in acute respiratory distress syndrome (ARDS) patients: a narrative review

Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies

Lessons to learn from epidemiologic studies in ARDS

Management of ARDS - What Works and What Does Not

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Acute respiratory distress syndrome: A review of ARDS across the life course

[Advances in the Diagnosis and Treatment of Pediatric Acute Respiratory Distress Syndrome].

Identification of Three Classes of Acute Respiratory Distress Syndrome Using Latent Class Analysis

The Acute Respiratory Distress Syndrome in 2013

What's Next After ARDS: Long-Term Outcomes